Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
Dj. Kereiakes et al., Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention, AM J CARD, 84(4), 1999, pp. 391-395
Citations number
25
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Adjunctive platelet glycoprotein IIb/IIIa blockade during percutaneous coro
nary intervention (PCI) reduces platelet mediated adverse ischemic outcomes
, Although abciximab, eptifibatide, and tirofiban have received U.S. Food a
nd Drug Administration approval for use, these agents differ in their pharm
acodynamic profiles. Each of these agents has been compared in randomized t
rials with placebo for patients undergoing PCI, but no randomized comparati
ve studies of these agents have been performed. We compared ex vivo platele
t function by both standard light transmission aggregometry and rapid plate
let function assay during and after administration of abciximab, eptifibati
de, or tirofiban in approved dose regimens on a randomized basis at the tim
e of PCI in patients with unstable angina pectoris. A reduced intensity of
platelet inhibition by light transmission aggregometry wets observed for ti
rofiban compared with either eptifibatide or abciximab. In addition, the 30
-minute bolus strategy used for tirofiban was associated with delayed onset
of maximal platelet inhibition relative to the initiation of bolus infusio
n. Whether the trends in platelet function observed in this study will be t
ranslated into differences in clinical outcomes awaits definition by larger
scale randomized clinical trials comparing these platelet glycoprotein IIb
/IIIa inhibitors. (C) 1999 by Excerpta Medica, Inc.